113P Translational analysis of acasunlimab in combination with pembrolizumab in CPI-treated metastatic NSCLC

Acasunlimab (DuoBody®-PD-L1x4-1BB) is a bispecific antibody immunotherapy designed to reinvigorate antitumor activity via conditional 4-1BB activation dependent on co-PD-L1 binding. Acasunlimab was evaluated in a Ph2 study (NCT05117242) in checkpoint inhibitor (CPI)- and chemotherapy (chemo)-treated PD-L1+ metastatic NSCLC as monotherapy (Arm A: 100 mg Q3W x2 cycles then 500 mg Q6W) or in combination (combo) with pembrolizumab (pembro) to maximize PD-1 blockade (Arm B: 100 mg + pembro 200 mg Q3W; Arm C: 100 mg + pembro 400 mg Q6W).